Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases from Italy

Vincenzo Montano, Francesco Gruosso, Valerio Carelli, Giacomo Pietro Comi, Massimiliano Filosto, Costanza Lamperti, Tiziana Mongini, Olimpia Musumeci, Serenella Servidei, Paola Tonin, Antonio Toscano, Angela Modenese, Guido Primiano, Maria Lucia Valentino, Sara Bortolani, Silvia Marchet, Megi Meneri, Graziana Tavilla, Gabriele Siciliano, Michelangelo Mancuso

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine whether a set of functional tests, clinical scales, patient-reported questionnaires, and specific biomarkers can be considered reliable outcome measures in patients with primary mitochondrial myopathy (PMM), we analyzed a cohort of Italian patients.

Methods: Baseline data were collected from 118 patients with PMM, followed by centers of the Italian network for mitochondrial diseases. We used the 6-Minute Walk Test (6MWT), Timed Up-and-Go Test (x3) (3TUG), Five-Times Sit-To-Stand Test (5XSST), Timed Water Swallow Test (TWST), and Test of Masticating and Swallowing Solids (TOMASS) as functional outcome measures; the Fatigue Severity Scale and West Haven-Yale Multidimensional Pain Inventory as patient-reported outcome measures; and FGF21, GDF15, lactate, and creatine kinase (CK) as biomarkers.

Results: A total of 118 PMM cases were included. Functional outcome measures (6MWT, 3TUG, 5XSST, TWST, and TOMASS) and biomarkers significantly differed from healthy reference values and controls. Moreover, functional measures correlated with patients' perceived fatigue and pain severity. Patients with either mitochondrial or nuclear DNA point mutations performed worse in functional measures than patients harboring single deletion, even if the latter had an earlier age at onset but similar disease duration. Both the biomarkers FGF21 and GDF15 were significantly higher in the patients compared with a matched control population; however, there was no relation with severity of disease.

Conclusions: We characterized a large cohort of PMM by evaluating baseline mitochondrial biomarkers and functional scales that represent potential outcome measures to monitor the efficacy of treatment in clinical trials; these outcome measures will be further reinvestigated longitudinally to define the natural history of PMM.

Original languageEnglish
Pages (from-to)e519
JournalNeurology. Genetics
Volume6
Issue number6
DOIs
Publication statusPublished - Dec 2020

Fingerprint

Dive into the research topics of 'Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases from Italy'. Together they form a unique fingerprint.

Cite this